Phase II study of neoadjuvant chemotherapy with a metronomic regimen of paclitaxel + cyclophosphamide + capecitabine followed by 5-fluorouracil + epirubicin + cyclophosphamide in operable triple-negative breast cancer (JBCRG-13 study).

Authors

Kenji Higaki

Hiroshima City Hospital, Hiroshima, Japan

Kenji Higaki , Norikazu Masuda , Toshimi Takano , Nobuki Matsunami , Takashi Morimoto , Shoichiro Ohtani , Makiko Mizutani , Takeshi Miyamoto , Katsumasa Kuroi , Shinji Ohno , Satoshi Morita , Masakazu Toi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

A randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab, a PD-L1 antibody, to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC).

First Author: Sibylle Loibl

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER2-negative inflammatory breast cancer.

First Author: Naoko Matsuda

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER-2 negative inflammatory breast cancer.

First Author: Naoko Matsuda

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

A randomized phase II trial comparing docetaxel plus cyclophosphamide with epirubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for hormone receptor-negative breast cancer: Kanagawa Breast Oncology Croup (KBOG) 1101 study.

First Author: Takashi Ishikawa